Effexor ad cited by FDA as misleading

Share this article:

The FDA's Division of Drug Marketing, Advertising, and Communications says a Wyeth professional journal ad for Effexor XR (venlaxine HCl) tablets was misleading because it overstated the drug's efficacy, made unsubstantiated superiority claims and other unsubstantiated claims, and minimized risks.

A recent warning letter says Effexor is indicated for treating major depressive disorder, among other things. The labeling says its use is associated with a number of serious risks and includes a black-box warning regarding suicide. There are also warnings for worsening and suicide risk, the need to screen patients for bipolar disorder, the potential for interactions with MAOIs, serotonin syndrome, hypertension and mydriasis.

The warning letter says the ad's claim that nearly 60% of patients who failed previous antidepressant treatment achieved remission when changed to Effexor was based on a study that for several reasons failed to support the magnitude of the claimed response rate and any conclusion that Effexor is superior to alternatives.

The letter says, by selecting only patients who responded to Effexor XR to continue to the next treatment phase, and by failing to properly account for potential recurrent depressive episodes in those patients who discontinued Effexor XR, the study design was biased in favor of Effexor XR.

Finally, the letter says, the ad's claim that over 20 million patients were treated with Effexor was also misleading. 
Share this article:

Email Newsletters

More in News

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.